Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alar Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was NT$5,499.16 Mil.
Alar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-52.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals EV-to-EBIT Related Terms
Alar Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's EV-to-EBIT falls into.
Alar Pharmaceuticals's current Enterprise Value is NT$3,775.72 Mil.
Alar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-52.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a EV-to-EBIT of -72.02 as of Sep. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alar Pharmaceuticals and its competitors. According to the industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Alar Pharmaceuticals' EV-to-EBIT too high?
Alar Pharmaceuticals' current EV-to-EBIT is -72.02. Based on the distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies for EV-to-EBIT. This places Alar Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current EV-to-EBIT is -72.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Fairly Valued. The stock's GF Value™ is NT$92.16, compared to a current price of NT$90.70 — trading 1.6% below its estimated fair value. The current EV-to-EBIT is -72.02. Alar Pharmaceuticals' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current EV-to-EBIT is -72.02 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$90.70 is trading 1.6% below its estimated GF Value™ of NT$92.16.
GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.
Key valuation signals for ROCO:6785:
EV-to-EBIT: -72.02
GF Value™: NT$92.16 vs. price of NT$90.70 (1.6% below fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
56GF Score
Get the complete analysis for ROCO:6785
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
